Wave Life Sciences falls as obesity drug fails to show promise in early-stage trial

Wave Life Sciences

26/03/2026 12:29

** Shares of drug developer Wave Life Sciences WVE.O fall 56.2% to $5.39 premarket

** Co says its experimental obesity drug showed a less than 1% reduction in average body weight compared to placebo in an early-stage trial

** Co says a 240 milligram dose of the drug called WVE-007 showed a placebo-adjusted reduction in body weight of 0.9% after  6 months

     ** Co says the drug was safe and well tolerated, says it is on track to start a mid-stage study testing  WVE-007 as a monotherapy in individuals with higher BMI and comorbidities in Q2

** Up to last close, stock down 27.7% YTD

 (Reporting by Sneha S K)

 ((Sneha.SK@thomsonreuters.com;))